Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score® test has been categorized as the only "preferred"...
Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of real-world clinical evidence demonstrating that use of the Oncotype DX Genomic ...
Genomic Health, Inc. (NASDAQ: GHDX) today announced the publication of an updated assessment of breast cancer gene expression profiling tests by the...
Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended June 30, 2018. "We delivered record...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 2 at 4:30 p.m....
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the Jefferies 2018 Global Healthcare Conference in New York City on...
Genomic Health, Inc. (NASDAQ: GHDX) today announced results from two new studies demonstrating the positive impact of the Oncotype DX® Genomic...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las...
Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended March 31, 2018. "In the first...
Genomic Health, Inc. (NASDAQ: GHDX) has been informed of the acceptance of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, ...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, May 2 at 4:30 p.m. Eastern ...
Genomic Health, Inc. (NASDAQ: GHDX) was informed by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) that the Trial Assigning IndividuaLized Options ...
Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2017. Total...
Genomic Health, Inc. (NASDAQ: GHDX) today announced the U.S. commercial launch of the Oncotype DX® AR-V7 Nucleus Detect™ test. The first and only...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Thursday, March 8 at 8:30 a.m....
Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of real-world clinical evidence demonstrating that use of the Oncotype DX®...
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at...
Genomic Health, Inc. (NASDAQ: GHDX) today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence...
Genomic Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present 10 Oncotype DX® studies at the 40th San Antonio Breast Cancer Symposium...
Genomic Health, Inc. (Nasdaq: GHDX), the world's leading provider of genomic-based diagnostic tests, and Cleveland Diagnostics, Inc., a biotechnology ...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 29th Annual Piper Jaffray Healthcare Conference in New York City on...
Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended September 30, 2017. Total revenue...
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, November 8 at 4:30 p.m....
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.